



Seminar on Biotech and Pharmaceuticals

**Theme : Overview & Linkage
between Biotech and Pharma**



**Willamson Magor Hall,
The Bengal Chamber of Commerce and Industry**



11th September, 2024, ⌚ 4 pm onwards



Prof. (Dr.) Dhrubajyoti Chattopadhyay

Prof. (Dr.) Dhrubajyoti Chattopadhyay is currently the Hon'ble Vice Chancellor of Sister Nivedita University, Kolkata from January 2020 onwards.

Prof. (Dr.) Dhrubajyoti Chattopadhyay is a scientist and academic par excellence. He has an established track record of highly innovative ideas and in-depth research activities. He is an excellent communicator with an impressive logical approach of delivery and communicating ability. His gifted communication skills make him an excellent class room teacher. His amiable personality and willingness to share group responsibilities allow him to be a precious member of any administration team.



Mr. Debarshi Dutta Gupta

Mr. Debarshi Dutta Gupta is the Managing Director of East India Pharmaceutical Works Ltd. and the Co-Chairperson of the Biotech and Pharma Committee of The Bengal Chamber of Commerce and Industry.



Mr. Barun Kanta Bhattacharyya

- ✓ Ph.D. in the field of Microbiology
- ✓ More than twenty four years of industrial R&D experience
- ✓ Life member of Biotech Research Society India (BRSI) and Association of Microbiologists of India (AMI)
- ✓ Editorial Board member of Biotech Express Magazine
- ✓ Member of BOS (Board of Studies) ST. Xavier's College, Biotechnology Department
- ✓ Papers in International peer reviewed journals and have one patent
- ✓ Worked with different Research Institutes (NCL, Pune; NICED, Kolkata) and commercial organizations (Chr. Hansen, Denmark; Advanced Enzymes, Unique Biotech) in different collaborative projects.



Dr. Debdutta Bandyopadhyay

Dr. Debdutta Bandyopadhyay is a cell biologist. He pursued his doctorate studies from Indian Institute of Chemical Biology (IICB) and received his PhD degree in 1994 from Jadavpur University. From 1995 to 2001 he continued his post-doctoral studies in Tulane University, New Orleans, MD Anderson Cancer Centre and Baylor College of Medicine, Houston, USA. In 2002, he assumed a faculty position in Baylor College of Medicine and continued till 2006. He turned to India in the same year and joined Zydus Research Centre as Deputy General Manager. During his tenure in Zydus, he served as General Manager and Senior General Manager and assumed the role of the Head of the Cell Biology and Invitro biology. In 2023, he joined ATGC Diagnostics as Senior Advisor (Training).



Dr. Sangita Sen Majee

Dr. Sangita Majee, Head, IKP-PRIME RTTO, A-LABS, IKP Knowledge Park
A biotechnologist with more than 20 years of industrial and academic experience in Research & Development, Quality Control, Analytical R&D, CRO Project Management, and Innovation Management. Skilled in designing, execution, commissioning and management of biopharmaceuticals development. Having wide experience in managing start-ups in domain of pharma, biopharma & industrial biotech.

Dr. Majee possesses in-depth and extensive end to end knowledge of development and quality control of Biologics (Biosimilars, Plasma Products). Knowledge in pre-clinical toxicity study (GLP and non-GLP) and regulatory dossier submission, familiarity with grant writing. Actively participated in regulatory audits (e.g. ANVISA), and ISO.



Dr. Susanta Roychoudhury

Dr. Susanta Roychoudhury is a cancer biologist. He obtained his PhD (Biochemistry) degree in 1985 from the University of Calcutta, India.

He also served as Chief, Basic Research, Saroj Gupta Cancer Centre & Research Institute, Kolkata from 2015-2021. Currently, Dr. Roychoudhury is the ICMR Emeritus Scientist at CSIR-Indian Institute of Chemical Biology, Kolkata. Dr. Roychoudhury is also Chairman, Board of Directors, ATGC Diagnostics Pvt. Ltd., a knowledge-based start-up at Kolkata.

Dr. Roychoudhury is among the first few who initiated genomic research in India. As a cancer biologist, he contributed significantly on the molecular understanding of the genomic instabilities, and functional consequences of gain-of function p53 mutations in human cancer.